Sudo Bio

Market position

Sudo describes its candidates as potential first- and best-in-class within TYK2 inhibition, differentiating on brain penetrance for CNS indications and on topical delivery for dermatology. Its investors note that TYK2 inhibition has already shown benefit in psoriasis, psoriatic arthritis and lupus, and that Sudo is extending the mechanism into neuroinflammatory and neurodegenerative settings including MS, Alzheimer's disease and ALS.

Differentiation rests on targeting the TYK2 pseudokinase domain for selectivity over other JAK family members, and on fit-for-purpose molecule design: a fully CNS-penetrant oral candidate (SUDO-550) intended to treat both relapsing and progressive multiple sclerosis and neuroinflammatory neurodegeneration, alongside a topical candidate intended for dermatologic indications.

Technology

Sudo's compounds are highly potent small-molecule inhibitors that bind the TYK2 pseudokinase (JH2) regulatory domain, an allosteric mechanism intended to block TYK2-mediated IL-12, IL-23 and type I interferon signaling while avoiding inhibition of JAK1 and JAK2, whose catalytic domains are highly conserved across the JAK family. SUDO-550 is engineered for CNS penetration and oral dosing so that it can act on immune cells peripherally and on neurons and glial cells within the central nervous system, addressing both acute inflammatory relapse biology and chronic neuroinflammation. A separate program is formulated for topical dermal delivery. The company cites human genetic evidence—loss-of-function TYK2 variants that lower multiple sclerosis risk and reduce IL-12, IL-23 and type I IFN signaling responses—as target validation.

Go-to-market

Patients with immune-mediated inflammatory and neurological conditions, including multiple sclerosis (roughly one million people affected in the United States, per the company), psoriasis and other immune-mediated dermatologic diseases, and neurodegenerative diseases with neuroinflammatory components such as Alzheimer's disease, ALS and Parkinson's disease.

Geography

Company communications list Sudo Biosciences as based in Carmel, Indiana, with operations across the United States and the United Kingdom.

History

Sudo Biosciences was founded in 2020. It raised a $116 million Series B announced in December 2023, co-led by Enavate Sciences and TPG, then completed a second close of $30 million in January 2024 announced in February 2024, upsizing the round to $147 million. It dosed the first participants in a Phase 1 trial of SUDO-550 in December 2024, reported positive Phase 1 results in October 2025, and appointed a Chief Legal Officer in December 2025.